| Nome |
# |
|
Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial, file e309ade3-cf5d-3969-e053-3a05fe0a2c94
|
357
|
|
High-sensitivity assay for monitoring ESR1 mutations in circulating cell-free DNA of breast cancer patients receiving endocrine therapy, file e309ade2-acd1-3969-e053-3a05fe0a2c94
|
123
|
|
miR-199a-3p Modulates MTOR and PAK4 Pathways and Inhibits Tumor Growth in a Hepatocellular Carcinoma Transgenic Mouse Model, file e309ade1-dfbb-3969-e053-3a05fe0a2c94
|
95
|
|
Nine weeks versus 1 year adjuvant trastuzumab in combination with chemotherapy: Final results of the phase III randomized Short-HER study, file e309ade2-1b03-3969-e053-3a05fe0a2c94
|
82
|
|
HER2-Positive Lobular Versus Ductal Carcinoma of the Breast: Pattern of First Recurrence and Molecular Insights, file e309ade2-a27d-3969-e053-3a05fe0a2c94
|
82
|
|
Endocrine therapy for hormone receptor-positive, HER2-negative metastatic breast cancer: Extending endocrine sensitivity, file e309ade2-7351-3969-e053-3a05fe0a2c94
|
80
|
|
Absolute quantification of cell-free microRNAs in cancer patients, file e309ade2-a818-3969-e053-3a05fe0a2c94
|
80
|
|
Association of Systemic Inflammation Index and Body Mass Index with Survival in Patients with Renal Cell Cancer Treated with Nivolumab, file e309ade2-2e86-3969-e053-3a05fe0a2c94
|
78
|
|
Prospective biomarker analysis of the randomized CHER-LOB study evaluating the dual anti-HER2 treatment with trastuzumab and lapatinib plus chemotherapy as neoadjuvant therapy for HER2-positive breast cancer, file e309ade1-6698-3969-e053-3a05fe0a2c94
|
72
|
|
Circulating miR-106b-3p, miR-101-3p and miR-1246 as diagnostic biomarkers of hepatocellular carcinoma, file e309ade1-c4c2-3969-e053-3a05fe0a2c94
|
72
|
|
Prevalence of malnutrition in patients at first medical oncology visit: The PreMiO study, file e309ade1-89e0-3969-e053-3a05fe0a2c94
|
69
|
|
Efficacy and safety of Everolimus and Exemestane in hormone-receptor positive (HR+) human-epidermal-growth-factor negative (HER2-) advanced breast cancer patients: New insights beyond clinical trials. The EVA study, file e309ade3-b451-3969-e053-3a05fe0a2c94
|
59
|
|
Phase II study of eribulin in combination with gemcitabine for the treatment of patients with locally advanced or metastatic triple negative breast cancer (ERIGE trial). Clinical and pharmacogenetic results on behalf of the Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC), file e309ade3-c960-3969-e053-3a05fe0a2c94
|
55
|
|
Role of innate and adaptive immunity in the efficacy of anti-HER2 monoclonal antibodies for HER2-positive breast cancer, file cea96229-0740-4178-b9f0-92f28d05a5c9
|
52
|
|
Association of tumor-infiltrating lymphocytes with distant disease-free survival in the ShortHER randomized adjuvant trial for patients with early HER2+ breast cancer, file e309ade2-1b04-3969-e053-3a05fe0a2c94
|
51
|
|
Validation of the AJCC prognostic stage for HER2-positive breast cancer in the ShortHER trial, file e309ade2-6b01-3969-e053-3a05fe0a2c94
|
51
|
|
Molecular testing on bronchial washings for the diagnosis and predictive assessment of lung cancer, file e309ade2-a3c7-3969-e053-3a05fe0a2c94
|
51
|
|
Patient and Health Care Professional Perspectives: A Case Study of the Lung Cancer Integrated Care Pathway, file e309ade2-1b05-3969-e053-3a05fe0a2c94
|
46
|
|
De-escalated therapy for HR+/HER2+ breast cancer patients with Ki67 response after 2-week letrozole: Results of the PerELISA neoadjuvant study, file e309ade2-3674-3969-e053-3a05fe0a2c94
|
46
|
|
Immune Checkpoint Inhibitors and Radiotherapy in NSCLC Patients: Not Just a Fluke, file e309ade3-dbbb-3969-e053-3a05fe0a2c94
|
43
|
|
Liquid biopsy testing can improve selection of advanced non-small-cell lung cancer patients to rechallenge with gefitinib, file e309ade2-6b02-3969-e053-3a05fe0a2c94
|
39
|
|
Is There Still a Role for Endocrine Therapy Alone in HR+/HER2- Advanced Breast Cancer Patients? Results from the Analysis of Two Data Sets of Patients Treated with High-Dose Fulvestrant as First-Line Therapy in the Real-World Setting: The EVA and GIM-13 AMBRA Studies, file e309ade4-0314-3969-e053-3a05fe0a2c94
|
36
|
|
Everolimus (EVE) and exemestane (EXE) in patients with advanced breast cancer aged ≥ 65 years: new lessons for clinical practice from the EVA study, file e309ade1-e76d-3969-e053-3a05fe0a2c94
|
35
|
|
Multidisciplinary management improves survival at 1 year after surgical treatment for non-small-cell lung cancer: a propensity score-matched study, file e309ade3-4dc8-3969-e053-3a05fe0a2c94
|
32
|
|
The HERBA Study: A Retrospective Multi-Institutional Italian Study on Patients With Brain Metastases From HER2-Positive Breast Cancer, file e309ade5-2fb1-3969-e053-3a05fe0a2c94
|
30
|
|
Diagnostic and prognostic microRNAs in the serum of breast cancer patients measured by droplet digital PCR, file e309ade0-c0d6-3969-e053-3a05fe0a2c94
|
29
|
|
PIK3CA Mutation in the ShortHER randomized adjuvant trial for patients with early HER2þ breast cancer: Association with prognosis and integration with PAM50 subtype, file e309ade3-a933-3969-e053-3a05fe0a2c94
|
23
|
|
miR-199a-3p increases the anti-tumor activity of palbociclib in liver cancer models, file 9938b2a9-5ecc-40ed-b881-eb91ccff77c7
|
18
|
|
Il protocollo Diagnostico-Terapeutico e Assistenziale per il carcinoma mammario della Regione Emilia-Romagna. I edizione, file e309ade1-fbc8-3969-e053-3a05fe0a2c94
|
17
|
|
Circulating miR-106b-3p, miR-101-3p and miR-1246 as diagnostic biomarkers of hepatocellular carcinoma, file e309ade1-c508-3969-e053-3a05fe0a2c94
|
16
|
|
The Molecular Networks of microRNAs and Their Targets in the Drug Resistance of Colon Carcinoma, file e309ade4-7e53-3969-e053-3a05fe0a2c94
|
14
|
|
Preoperative chemotherapy plus trastuzumab, lapatinib, or both in human epidermal growth factor receptor 2-positive operable breast cancer: Results of the randomized phase II CHER-LOB study, file e309ade1-71b3-3969-e053-3a05fe0a2c94
|
13
|
|
Trends in net survival from liver cancer in six European Latin countries: results from the SUDCAN population-based study, file e309ade1-33ef-3969-e053-3a05fe0a2c94
|
12
|
|
Tumor infiltrating lymphocytes in triple negative breast cancer and correlations with prognosis, file 9c6d6fff-3161-4ec0-97c9-89c42ffa924a
|
10
|
|
Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial, file ceea5e19-44a0-4cf4-9b3a-a840d10ff600
|
9
|
|
Diagnostic and prognostic microRNAs in the serum of breast cancer patients measured by droplet digital PCR, file e309ade0-c80f-3969-e053-3a05fe0a2c94
|
8
|
|
A prognostic model based on nodal status and Ki-67 predicts the risk of recurrence and death in breast cancer patients with residual disease after preoperative chemotherapy, file e309ade1-6cc5-3969-e053-3a05fe0a2c94
|
8
|
|
Phase 2 study of NAB-paclitaxel in SensiTivE and refractory relapsed small cell lung cancer (SCLC) (NABSTER TRIAL), file e309ade3-aa11-3969-e053-3a05fe0a2c94
|
8
|
|
Clinical-diagnostic relevance of breast “incidentaloma” detected during 18F-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography: Correlation with radiological imaging and histopathology, file e309ade5-1cf9-3969-e053-3a05fe0a2c94
|
8
|
|
Immune Checkpoint Inhibitors in “Special” NSCLC Populations: A Viable Approach?, file 4f677aec-5fa8-4af2-ae79-21f44fec3d88
|
7
|
|
Estrogen receptor mutation: a new strategy to overcome endocrine resistance, file 8f1c9a9a-391d-441b-b9b3-8c9803bb2d76
|
7
|
|
Which elderly newly diagnosed glioblastoma patients can benefit from radiotherapy and temozolomide? A PERNO prospective study, file e309ade2-b8bb-3969-e053-3a05fe0a2c94
|
7
|
|
Immune microenvironment and intrinsic subtyping in hormone receptor-positive/HER2-negative breast cancer, file e309ade3-d3ee-3969-e053-3a05fe0a2c94
|
7
|
|
A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluation, file 97a71bd9-ce36-4c51-afed-fd85e0e929aa
|
6
|
|
Predictive value of biologic parameters for primary chemotherapy in operable breast cancer, file e309ade1-6e64-3969-e053-3a05fe0a2c94
|
6
|
|
Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO-FAST study): Final 60-month results, file e309ade1-7181-3969-e053-3a05fe0a2c94
|
6
|
|
Association of Systemic Inflammation Index and Body Mass Index with Survival in Patients with Renal Cell Cancer Treated with Nivolumab, file e309ade4-3940-3969-e053-3a05fe0a2c94
|
6
|
|
Gastrointestinal stromal tumors and other malignancies: A case series, file e309ade1-6ab8-3969-e053-3a05fe0a2c94
|
5
|
|
Changes of biological features in breast cancer cells determined by primary chemotherapy, file e309ade1-6f84-3969-e053-3a05fe0a2c94
|
5
|
|
Hairy cell leukemia: the Italian Cooperative Group experience, file e309ade1-745c-3969-e053-3a05fe0a2c94
|
5
|
|
A multiparametric approach to improve the prediction of response to immunotherapy in patients with metastatic NSCLC, file e309ade3-ccb5-3969-e053-3a05fe0a2c94
|
5
|
|
Overall Survival in Metastatic Breast Cancer Patients in the Third Millennium: Results of the COSMO Study, file e309ade3-f07a-3969-e053-3a05fe0a2c94
|
5
|
|
Overall Survival in Metastatic Breast Cancer Patients in the Third Millennium: Results of the COSMO Study, file ab817719-e610-4d85-aa05-a83e894d7ed4
|
4
|
|
Preoperative chemotherapy plus lapatinib or trastuzumab or both in HER2-positive operable breast cancer (CHERLOB trial), file e309ade1-6e3d-3969-e053-3a05fe0a2c94
|
4
|
|
Formestane, a steroidal aromatase inhibitor after failure of non-steroidal aromatase inhibitors (anastrozole and letrozole): is a clinical benefit still achievable?, file e309ade1-6e83-3969-e053-3a05fe0a2c94
|
4
|
|
Posterior reversible encephalopathy syndrome during ipilimumab therapy for malignant melanoma, file e309ade1-728f-3969-e053-3a05fe0a2c94
|
4
|
|
Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial, file e309ade1-e770-3969-e053-3a05fe0a2c94
|
4
|
|
Nivolumab and brain metastases in patients with advanced non-squamous non-small cell lung cancer, file e309ade2-3673-3969-e053-3a05fe0a2c94
|
4
|
|
Efficacy and safety of Everolimus and Exemestane in hormone-receptor positive (HR+) human-epidermal-growth-factor negative (HER2-) advanced breast cancer patients: New insights beyond clinical trials. The EVA study, file e309ade2-b6ed-3969-e053-3a05fe0a2c94
|
4
|
|
Role of PSMA-ligands imaging in Renal Cell Carcinoma management: current status and future perspectives, file e309ade5-46b6-3969-e053-3a05fe0a2c94
|
4
|
|
A multiparametric approach to improve the prediction of response to immunotherapy in patients with metastatic NSCLC, file d6a71a76-1258-4a30-b8f0-e68ae26031a9
|
3
|
|
Safety and tolerability of subcutaneous trastuzumab for the adjuvant treatment of human epidermal growth factor receptor 2-positive early breast cancer: SafeHer phase III study's primary analysis of 2573 patients, file e309ade1-5e9d-3969-e053-3a05fe0a2c94
|
3
|
|
The promher study: An observational Italian study on adjuvant therapy for her2-positive, pT1a-b pN0 breast cancer, file e309ade1-5fc8-3969-e053-3a05fe0a2c94
|
3
|
|
Synchronous papillary carcinoma and hemangiopericytoma with lung metastases, file e309ade1-6a81-3969-e053-3a05fe0a2c94
|
3
|
|
Splenectomy after initial therapy with alpha-IFN in patients with hairy-cell leukemia (HCL): a multi-center study by the Italian Cooperative Group for HCL. Preliminary results, file e309ade1-7153-3969-e053-3a05fe0a2c94
|
3
|
|
Double-blind, placebo-controlled, multicenter, randomized, phase IIB neoadjuvant study of letrozole-lapatinib in postmenopausal hormone receptor-positive, human epidermal growth factor receptor 2-negative, operable breast cancer, file e309ade1-748e-3969-e053-3a05fe0a2c94
|
3
|
|
Prognostic impact of interval breast cancer detection in women with pT1a N0M0 breast cancer with HER2-positive status: Results from a multicentre population-based cancer registry study, file e309ade1-b64d-3969-e053-3a05fe0a2c94
|
3
|
|
Neoadjuvant treatment with trastuzumab and pertuzumab plus palbociclib and fulvestrant in HER2-positive, ER-positive breast cancer (NA-PHER2): An exploratory, open-label, phase 2 study, file e309ade1-e771-3969-e053-3a05fe0a2c94
|
3
|
|
Can irinotecan dose reduction according to ugt1a1 genotype avoid severe toxicities?, file e309ade2-9dcb-3969-e053-3a05fe0a2c94
|
3
|
|
18F-Choline PET/CT or PET/MR and the evaluation of response to systemic therapy in prostate cancer: are we ready?, file 3cb9165c-7a5e-4b2d-b345-15635e43fa6e
|
2
|
|
Erratum: miR-199a-3p increases the anti-tumor activity of palbociclib in liver cancer models, file 68254c94-40d3-4ab4-9560-8a3228b44b7c
|
2
|
|
Impressive response to dose-dense chemotherapy in a patient with NUT midline carcinoma, file e309ade1-5edc-3969-e053-3a05fe0a2c94
|
2
|
|
Epirubicin plus low-dose trastuzumab in HER2 positive metastatic breast cancer, file e309ade1-6ef6-3969-e053-3a05fe0a2c94
|
2
|
|
Vinblastine, bleomycin, and methotrexate chemotherapy plus extended-field radiotherapy in early, favorably presenting, clinically staged Hodgkin's patients: the Gruppo Italiano per lo Studio dei Linfomi Experience, file e309ade1-7090-3969-e053-3a05fe0a2c94
|
2
|
|
Adipose-derived mesenchymal stem cells as stable source of tumor necrosis factor-related apoptosis-inducing ligand delivery for cancer therapy, file e309ade1-71ef-3969-e053-3a05fe0a2c94
|
2
|
|
Patients with NSCLC may display a low ratio of p.T790M vs. activating EGFR mutations in plasma at disease progression: Implications for personalised treatment, file e309ade1-87d4-3969-e053-3a05fe0a2c94
|
2
|
|
Current views on anthracycline cardiotoxicity, file e309ade1-88dc-3969-e053-3a05fe0a2c94
|
2
|
|
Ovarian endometrioid adenocarcinoma with a yolk sac tumor component in a postmenopausal woman: Case report and review of the literature, file e309ade1-8ed1-3969-e053-3a05fe0a2c94
|
2
|
|
The HERBA Study: A Retrospective Multi-Institutional Italian Study on Patients With Brain Metastases From HER2-Positive Breast Cancer, file e309ade2-3672-3969-e053-3a05fe0a2c94
|
2
|
|
Italian cohort of the nivolumab EAP in squamous NSCLC: Efficacy and safety in patients with CNS metastases, file e309ade2-6b00-3969-e053-3a05fe0a2c94
|
2
|
|
Immune-related adverse events correlate with clinical outcomes in NSCLC patients treated with nivolumab: The Italian NSCLC expanded access program, file e309ade2-6d87-3969-e053-3a05fe0a2c94
|
2
|
|
Role of PSMA-ligands imaging in Renal Cell Carcinoma management: current status and future perspectives, file f6fe0ff5-e07a-42fc-a8b6-1bd06614e074
|
2
|
|
Reversibility of Left Ventricle Longitudinal Strain Alterations Induced by Adjuvant Therapy in Early Breast Cancer Patients, file e309ade0-ce40-3969-e053-3a05fe0a2c94
|
1
|
|
"Triple positive" early breast cancer: An observational multicenter retrospective analysis of outcome, file e309ade1-6024-3969-e053-3a05fe0a2c94
|
1
|
|
Adherence to AIOM (Italian Association of Medical Oncology) lung cancer guidelines in Italian clinical practice: Results from the RIGHT-3 (research for the identification of the most effective and highly accepted clinical guidelines for cancer treatment) study, file e309ade1-66c9-3969-e053-3a05fe0a2c94
|
1
|
|
Risk of second cancer in patients with hairy cell leukemia: long-term follow-up, file e309ade1-6796-3969-e053-3a05fe0a2c94
|
1
|
|
The management of skin toxicity during cetuximab treatment in advanced colorectal cancer: How much does it cost? A retrospecive economic assessment from a single-center experience, file e309ade1-680b-3969-e053-3a05fe0a2c94
|
1
|
|
Gene expression profiling in breast cancer: A clinical perspective, file e309ade1-6849-3969-e053-3a05fe0a2c94
|
1
|
|
Pulmonary strongyloidiasis mimicking cancer symptoms: A case of hyperinfection in a patient with metastatic lung cancer, file e309ade1-6858-3969-e053-3a05fe0a2c94
|
1
|
|
Primary systemic therapy in operable breast cancer: Clinical data and biological fall-out, file e309ade1-69a8-3969-e053-3a05fe0a2c94
|
1
|
|
Intra-arterial chemotherapy for unresectable pancreatic cancer, file e309ade1-69ab-3969-e053-3a05fe0a2c94
|
1
|
|
HER2 overexpression as a predictive marker in a randomized trial comparing adjuvant cyclophosphamide/methotrexate/5-fluorouracil with epirubicin in patients with stage I/II breast cancer: long-term results, file e309ade1-6be9-3969-e053-3a05fe0a2c94
|
1
|
|
Adjuvant systemic therapies in women with breast cancer: an audit of clinical practice in Italy, file e309ade1-6d4f-3969-e053-3a05fe0a2c94
|
1
|
|
GMP-manufactured density gradient media for optimized mesenchymal stromal/stem cell isolation and expansion, file e309ade1-6e7a-3969-e053-3a05fe0a2c94
|
1
|
|
Immediate administration of zoledronic acid reduces aromatase inhibitorassociated bone loss in postmenopausal women with early breast cancer: 12-month analysis of the E-ZO-FAST trial, file e309ade1-6eb3-3969-e053-3a05fe0a2c94
|
1
|
|
Adjuvant hormonal therapy and fertility preservation in premenopausal breast cancer: A survey among Italian oncologists, file e309ade1-6f26-3969-e053-3a05fe0a2c94
|
1
|
|
Primary systemic therapy for operable breast cancer: A review of clinical trials and perspectives, file e309ade1-714d-3969-e053-3a05fe0a2c94
|
1
|
|
Letrozole versus letrozole plus lapatinib (GW572016) in hormone-sensitive, HER2-negative operable breast cancer: A double-blind, randomized, phase II study with biomarker evaluation (EGF109077-LAP107692/LETLOB), file e309ade1-7183-3969-e053-3a05fe0a2c94
|
1
|
|
Aromatase inhibitors in the adjuvant treatment of postmenopausal women with early breast cancer: Putting safety issues into perspective, file e309ade1-7266-3969-e053-3a05fe0a2c94
|
1
|
|
Role of interferon-alpha administration after 2-deoxycoformycin in the treatment of hairy cell leukemia patients, file e309ade1-73f1-3969-e053-3a05fe0a2c94
|
1
|
| Totale |
2.189 |